234 results
Page 3 of 12
40-F
EX-99.2
p3y4b1y
23 Feb 22
Annual report (Canada)
5:20pm
6-K
EX-99.1
hafoj6a5gq2s
23 Feb 22
BELLUS Health Reports Year 2021 Financial Results and Business Highlights
4:01pm
6-K
EX-99.1
coldp 0vo
17 Dec 21
BELLUS Health Closes US$200 Million Public Offering of Common Shares in Canada and the United States
4:03pm
6-K
EX-99.1
7aiar
15 Dec 21
BELLUS Health Announces Pricing of US$200 Million Public Offering in Canada and the United States
5:15pm
6-K
EX-99.2
vy1 znfnmmv1tcl
15 Dec 21
BELLUS Health Announces Pricing of US$200 Million Public Offering in Canada and the United States
5:15pm
SUPPL
xrv68m
15 Dec 21
Supplemental materials (foreign)
5:10pm
F-10
vppo6sd98tcr54bjm
14 Dec 21
Registration of securities (Canada)
9:43am
SUPPL
yd2izop6 9pynpsr
13 Dec 21
Supplemental materials (foreign)
5:00pm
6-K
EX-99.1
cjdwtk
13 Dec 21
BELLUS Health Announces the Launch of a Public Offering of Common Shares in Canada and the United States
4:07pm
6-K
EX-99.1
fspbc3
13 Dec 21
BELLUS Health Announces Positive Topline Results from its Phase 2b SOOTHE Trial of BLU-5937 for the Treatment of Refractory Chronic Cough
7:19am
6-K
EX-99.2
7d5p2eb2ts cb
13 Dec 21
BELLUS Health Announces Positive Topline Results from its Phase 2b SOOTHE Trial of BLU-5937 for the Treatment of Refractory Chronic Cough
7:19am
6-K
EX-99.1
vj0vw5bbkun084 h58
13 Dec 21
BELLUS Health Announces Positive Topline Results from its Phase 2b SOOTHE Trial of BLU-5937 for the Treatment of Refractory Chronic Cough
7:00am
6-K
EX-99.3
r7p3dm99qdc83avrh dz
10 Nov 21
Condensed Consolidated Interim Financial Statements of
4:42pm
6-K
EX-99.4
7xdqw4rb ai3j8gb0gw
10 Nov 21
Condensed Consolidated Interim Financial Statements of
4:42pm
6-K
EX-99.1
rej96w99jo31d
10 Nov 21
BELLUS Health Reports Third Quarter 2021 Financial Results and Business Highlights
4:30pm
6-K
EX-99.1
1txdbwcm71q2o0
1 Nov 21
Bellus Health Inc. 6-K
7:00am
6-K
EX-99.1
fyc2fpmr 3v8t
23 Sep 21
Topline results from both studies are expected in December 2021
7:00am
6-K
EX-99.1
6ssiehvll1p4j
13 Sep 21
BELLUS Health Announces Positive Interim Analysis from the Phase 2b SOOTHE Trial of BLU-5937 in Refractory Chronic Cough
7:45am
6-K
EX-99.1
7n5ygcunndq
23 Aug 21
BELLUS Health to Report Additional RELIEF Data in an Oral Presentation at the European Respiratory Society International Congress 2021
7:00am
6-K
EX-99.4
uf84nh
11 Aug 21
Condensed Consolidated Interim Financial Statements of
4:43pm